Amgen Ventures
Amgen Ventures is the corporate venture capital and business development arm of Amgen Inc. (NASDAQ: AMGN), executing equity investments, co-development partnerships, in-licensing, out-licensing, and academic alliances in oncology, inflammation, general medicine, and rare disease.
- Company typePrivate
- Founded2014
- HeadquartersSan Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Amgen Ventures does
Amgen Ventures is the corporate venture capital and business development arm of Amgen Inc. (NASDAQ: AMGN), a fully-integrated biotechnology company. Headquartered within Amgen's Thousand Oaks, California campus with an additional presence in South San Francisco, the unit operates with 11-50 employees and pursues partnerships, equity investments, acquisitions, out-licensing arrangements, and academic alliances across the therapeutic areas of oncology, inflammation, general medicine, and rare disease. The entity was established as a formalized business development function in 2014 under the Amgen BD brand (amgenbd.com).
The unit's product surface is structured around five deal archetypes: venture investments (e.g., AAVantgarde Bio $141 million Series B in November 2025; Ember LifeSciences $27 million Series A in May 2026), strategic co-development collaborations (e.g., AstraZeneca's tezepelumab since 2012; BeiGene oncology alliance since 2019 valued at $2.7 billion for a 20.5% equity stake), in-licensing transactions (e.g., Arrowhead Pharmaceuticals' RNAi ARC-LPA cardiovascular program since 2016), out-licensing and spin-outs of internal assets (e.g., Vigil Neuroscience's TREM2 program in 2020), and academic research partnerships (Broad Institute, MIT, UCSF, Caltech, UCLA, University of Washington Institute for Protein Design, and Mila — Quebec AI Institute). Amgen Inc. has separately executed major acquisitions including ChemoCentryx, deCODE, Five Prime, Horizon, Micromet, Nuevolution, and Onyx.
The business model is not revenue-generating in the conventional sense; Amgen Ventures deploys capital from Amgen Inc.'s balance sheet and functions as a strategic deal-making engine rather than a fee-earning venture fund. It operates without third-party LP capital, does not charge management fees, and does not disclose standalone revenue. Value capture for the parent company comes through pipeline augmentation, geographic expansion (notably China via BeiGene), technology sourcing, and optionality on emerging modalities such as gene therapy, RNAi therapeutics, and generative biology.
Amgen Ventures firmographics
Firmographics- Name
- Amgen Ventures
- Legal name
- Amgen Inc.
- Website
- https://amgenbd.com
- Company type
- Private
- Founded year
- 2014
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Amgen Ventures is the corporate venture capital and business development arm of Amgen Inc. (NASDAQ: AMGN), executing equity investments, co-development partnerships, in-licensing, out-licensing, and academic alliances in oncology, inflammation, general medicine, and rare disease.
- Ownership category
- akta.pro rank
Amgen Ventures industry classification
Industry- Product category
- Biotech Venture Capital and Business Development
- NAICS
- Portfolio Management and Investment Advice (523940)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Corporate Strategic Partnership & Ecosystem Investment Arms (FSANAHAF)
Keywords
Where Amgen Ventures is headquartered
LocationHeadquarters
- HQ city
- San Francisco
- HQ country
- United States
- HQ region
- North America
Offices6 records
Markets served
Amgen Ventures business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Others
Distribution channels1 record
Marketing channels2 records
Amgen Ventures product offering
Product offeringCore offering
Amgen Ventures is the corporate venture capital and business development arm of Amgen Inc. It invests equity capital in early- and late-stage biotechnology companies and structures co-development, co-commercialization, acquisition, and out-license arrangements with biotech innovators and academic research institutions. The unit's mandate spans oncology, inflammation, general medicine, and rare disease therapeutics, leveraging Amgen's integrated discovery-through-commercialization capabilities.
Product overview
Amgen Business Development operates as a fully-integrated biotechnology partnership platform, offering multiple investment and collaboration structures rather than a unified product. The core offerings include Venture Investments (for early-stage biotech companies), Collaborations (co-development agreements), Acquisitions, Out-License and Spin-Outs (for asset externalization), Academic Partnerships (with research institutions), and Companion Diagnostics partnerships. Amgen supports the full life-cycle of drug development from human genetics and target validation through global commercialization, with therapeutic focus areas in oncology, inflammation, general medicine, and rare disease. Notable investment targets include Ember LifeSciences (cold chain logistics), AAVantgarde Bio (gene therapy), Strand Therapeutics (mRNA therapeutics), and Cartography Biosciences (antibody-based oncology).
Differentiator
Problem solved
Functional benefit
Brands
- Amgen BD: The branded identity for Amgen's business development and partnering activities, accessible via amgenbd.com
Products and services
- Venture Investments Strategic equity investments in early- and late-stage biotechnology companies developing novel therapeutics and platform technologies aligned with Amgen's focus areas (oncology, inflammation, general medicine, rare disease). For biotech founders and CSOs seeking corporate venture capital.
- Collaborations Co-development and co-commercialization partnerships with biotech innovators for joint advancement of therapeutic programs. Includes strategic collaborations such as AstraZeneca's tezepelumab co-development. For biotech companies seeking a development and commercialization partner.
- Acquisitions Strategic acquisitions of biotech companies with technologies and pipelines that complement Amgen's focus areas. Acquired entities include ChemoCentryx, deCODE, Five Prime, Horizon, KAI, Micromet, Nuevolution, Onyx, Otezla, and Rodeo. For biotech companies and shareholders seeking an exit and large-scale integration.
- Out-License and Spin-Outs Out-licensing and spin-out arrangements through which Amgen transfers internal assets or programs to dedicated companies (Akero, Bioage, Celimmune, Jasper, Kartos, Neumora, Vigil Neuroscience, Volastra, Voravi) for focused development. For external partners and biotech founders seeking assets and capital.
- Academic Partnerships Sponsored research and drug discovery collaborations with premier academic and research institutions including Broad Institute, Caltech, MIT, UCLA, UCSF, University of Washington Institute for Protein Designs, and Mila - Quebec AI Institute. For academic researchers and technology transfer offices seeking industry partnership.
- Companion Diagnostics Partnerships for companion diagnostics development alongside Amgen therapeutics with diagnostics developers including Adaptive, AmoyDx, Dako/Agilent, Foundation Medicine, Guardant Health, Qiagen, and Roche/Ventana. For diagnostic developers seeking a therapeutic anchor and for enabling precision medicine for Amgen's pipeline.
Companies that use Amgen Ventures
Customer profileSegments2 records
Ideal customer profiles2 records
Amgen Ventures technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Amgen Ventures partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core, flagship and minor.
- Vigil NeurosciencecoreAmgen out-licensed TREM2 programs to Vigil Neuroscience, a newly formed company co-founded and incubated by Atlas Venture. Vigil launched with $50 million Series A financing to progress TREM2 programs for neurodegenerative diseases.
- BeiGeneflagshipAmgen entered a strategic collaboration with BeiGene in 2019, investing $2.7 billion for a 20.5% stake. BeiGene commercializes XGEVA, KYPROLIS, and BLINCYTO in China. The companies collaborate on advancing Amgen's oncology pipeline, sharing global R&D costs with BeiGene contributing up to $1.25 billion alongside Amgen's investments.
- Arrowhead PharmaceuticalscoreAmgen entered licensing agreements with Arrowhead to develop RNAi therapies for cardiovascular disease. Amgen received exclusive worldwide license to Arrowhead's RNAi ARC-LPA program targeting elevated lipoprotein(a), plus option for an undisclosed cardiovascular target.
- AstraZenecaflagshipAmgen and AstraZeneca jointly develop and commercialize monoclonal antibodies including tezepelumab. AstraZeneca made a $50 million upfront payment with shared costs and profits. The partnership evolved to define each partner's roles for launch and commercialization.
- NuevolutioncoreA long-term collaboration that led to acquisition, expanding Amgen's ability to discover novel small molecules.
- Arrakis TherapeuticsminorCollaboration for RNA-targeted small molecule therapies.
- Generate BiomedicinesminorStrategic collaboration for generative biology and protein generation.
- Broad InstitutecoreAcademic partnership for research collaboration in drug discovery.
- MITcoreAcademic partnership for life sciences research.
- UCSFcoreAcademic partnership for biomedical research collaboration.
Scale indicators1 record
Recent moves6 records
Expansion highlights5 records
Amgen Ventures competitors and assessment
Company assessmentDirect peers
- Lilly Asia Ventures: Eli Lilly's venture arm with strong Asia/China focus. Comparable to Amgen Ventures' BeiGene-driven Asia strategy and biotech CVC model, though more regionally focused.
- Pfizer Ventures: Pfizer's corporate venture capital arm making minority equity investments in biotech companies. Similar to Amgen Ventures in deploying strategic capital to source external innovation aligned with Pfizer's therapeutic priorities.
- Novartis Venture Fund: Corporate venture capital arm of Novartis investing in biotech and life sciences. Closely comparable model to Amgen Ventures: pharma parent, therapeutic-aligned investing, focused on building pipeline optionality through early-stage equity.
- Roche Venture Fund: Roche's corporate venture arm investing in early- and late-stage biotech. Directly comparable to Amgen Ventures as both are pharma CVCs deploying strategic capital into therapeutics aligned with their parent's pipeline.
- Merck Global Health Innovation Fund: Merck's CVC arm investing across therapeutics, digital health, and life sciences tools. Directly comparable as a major pharma CVC with similar mandate to source external innovation through equity investments.
- Bristol-Myers Squibb Strategic Investments: BMS's CVC activity investing in biotech to support its oncology and specialty pipeline. Comparable as a major pharma CVC with similar therapeutic-area-driven investing mandate.
- Sanofi Ventures: Sanofi's CVC arm investing in early-stage biotech and digital health. Comparable to Amgen Ventures in pharma CVC structure, therapeutic-area-aligned investing, and ability to leverage parent's commercialization infrastructure.
- AbbVie Ventures: AbbVie's corporate venture capital arm investing in emerging biotech. Comparable to Amgen Ventures in being a top-10 pharma CVC focused on therapeutic-area-aligned equity investing to support parent pipeline.
- GlaxoSmithKline (SR One): GSK's biotech-focused venture arm. Comparable to Amgen Ventures as a pharma CVC deploying capital in early-stage biotech aligned with parent therapeutic priorities.
Broad incumbents
- Johnson & Johnson Innovation (JLABS): J&J's broader innovation arm including JLABS incubator and JJDC venture investing. Comparable as a pharma corporate innovation platform, though broader in scope including incubators and accelerators.
Market position
Strengths3 records
Weaknesses3 records
Competitive moat4 records
Key risks4 records
Key highlights6 records
Customer concentration
Amgen Ventures social profiles
Digital presenceAmgen Ventures financial estimates
Financial estimateRevenue estimate
Valuation estimate
Amgen Ventures leadership team
Management profileNumber of profiles
Profiles2 records
Amgen Ventures funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Amgen Ventures M&A and investment
M&A and investmentM&A
Investments136 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Amgen Ventures
What does Amgen Ventures do?
Amgen Ventures is the corporate venture capital and business development arm of Amgen Inc. It invests equity capital in early- and late-stage biotechnology companies and structures co-development, co-commercialization, acquisition, and out-license arrangements with biotech innovators and academic research institutions. The unit's mandate spans oncology, inflammation, general medicine, and rare disease therapeutics, leveraging Amgen's integrated discovery-through-commercialization capabilities.
Is Amgen Ventures a public or private company?
Amgen Ventures is a private company. It is classified as corporate owned and is currently operating.
When was Amgen Ventures founded?
Amgen Ventures was founded in 2014. It employs 11 to 50 people.
Where is Amgen Ventures based?
Amgen Ventures is headquartered in San Francisco, United States, in the North America region.
Who are Amgen Ventures's main competitors?
Direct peers on record are Lilly Asia Ventures, Pfizer Ventures, Novartis Venture Fund, Roche Venture Fund, Merck Global Health Innovation Fund, Bristol-Myers Squibb Strategic Investments, Sanofi Ventures, AbbVie Ventures and GlaxoSmithKline (SR One). Johnson & Johnson Innovation (JLABS) is listed as a broad incumbent.
Does Amgen Ventures have an API?
No public API is recorded for Amgen Ventures.
What industry is Amgen Ventures in?
Amgen Ventures's product category is Biotech Venture Capital and Business Development. Its primary akta.pro industry code is FSANAHAF, Corporate Strategic Partnership & Ecosystem Investment Arms. Its NAICS code is 523940 and its SIC code is 6282.